enGene (NASDAQ:ENGN) Given “Market Outperform” Rating at JMP Securities

JMP Securities reissued their market outperform rating on shares of enGene (NASDAQ:ENGN) in a research note released on Monday morning,Benzinga reports. JMP Securities currently has a $18.00 price target on the stock.

A number of other analysts have also weighed in on ENGN. Citizens Jmp upgraded shares of enGene to a “strong-buy” rating in a research report on Monday, November 18th. Oppenheimer reissued an “outperform” rating and set a $30.00 price objective on shares of enGene in a report on Tuesday, September 24th. HC Wainwright began coverage on enGene in a report on Monday. They issued a “buy” rating and a $25.00 target price for the company. Raymond James assumed coverage on enGene in a research report on Wednesday, November 27th. They issued an “outperform” rating and a $23.00 target price for the company. Finally, Morgan Stanley restated an “overweight” rating and set a $40.00 price target on shares of enGene in a report on Wednesday, September 11th. Ten equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $29.78.

enGene Price Performance

Shares of ENGN stock opened at $5.96 on Monday. enGene has a twelve month low of $4.42 and a twelve month high of $18.40. The company has a quick ratio of 19.52, a current ratio of 19.52 and a debt-to-equity ratio of 0.09. The business has a fifty day simple moving average of $8.13 and a 200 day simple moving average of $7.80. The company has a market cap of $263.53 million, a P/E ratio of -10.28 and a beta of -0.78.

enGene (NASDAQ:ENGN) last posted its earnings results on Thursday, December 19th. The company reported ($0.34) EPS for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.06. On average, sell-side analysts forecast that enGene will post -1.52 EPS for the current fiscal year.

Insider Activity at enGene

In other enGene news, CEO Ronald Harold Wilfred Cooper bought 10,000 shares of the stock in a transaction that occurred on Friday, September 27th. The shares were bought at an average price of $5.70 per share, for a total transaction of $57,000.00. Following the acquisition, the chief executive officer now directly owns 10,000 shares of the company’s stock, valued at approximately $57,000. The trade was a ∞ increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Growth Opportunities F. Forbion purchased 11,844 shares of the business’s stock in a transaction on Monday, October 7th. The shares were bought at an average price of $6.55 per share, with a total value of $77,578.20. Following the purchase, the insider now directly owns 2,469,833 shares in the company, valued at approximately $16,177,406.15. The trade was a 0.48 % increase in their position. The disclosure for this purchase can be found here. Insiders bought 420,965 shares of company stock valued at $2,651,103 in the last three months. Corporate insiders own 13.70% of the company’s stock.

Institutional Investors Weigh In On enGene

Several institutional investors have recently bought and sold shares of the stock. Logos Global Management LP lifted its stake in enGene by 50.0% during the 2nd quarter. Logos Global Management LP now owns 1,200,000 shares of the company’s stock valued at $11,316,000 after acquiring an additional 400,000 shares in the last quarter. Franklin Resources Inc. raised its holdings in shares of enGene by 48.7% in the third quarter. Franklin Resources Inc. now owns 1,189,952 shares of the company’s stock valued at $7,854,000 after purchasing an additional 389,918 shares during the last quarter. Point72 Asset Management L.P. lifted its position in shares of enGene by 1,410.3% during the third quarter. Point72 Asset Management L.P. now owns 663,000 shares of the company’s stock valued at $4,376,000 after purchasing an additional 619,100 shares in the last quarter. SR One Capital Management LP purchased a new position in enGene during the second quarter worth about $4,715,000. Finally, Wolverine Asset Management LLC bought a new stake in enGene in the 3rd quarter worth about $37,000. Institutional investors own 64.16% of the company’s stock.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.